Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or New Jersey for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to New Jersey only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. New Jersey (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Thomas Blom (NPI 1932304599)

Field	Value
Entity Type	Individual
Organization	Thomas Blom
Address	419 N Harrison St
City	Princeton
State	NJ
ZIP	08540
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	June 15, 2007

Payer Source	Total Paid
Medicare	$2.3M
Medicaid	$0

Key Findings

This provider’s billing is effectively single‑payer: Total Medicare revenue is $2.3M while Medicaid shows none on file, indicating the practice’s Medicare business dominates its public-payer footprint. Analysts should treat Medicare patterns as representative of this clinician’s public payer activity because there is no Medicaid revenue to compare.

Revenue is highly concentrated in a small set of drug codes: the precomputed top three Medicare codes account for 79.8% of total Medicare revenue, led by J9144 $1.1M (47.8%), followed by J9271 $438.6K (19.2%) and J0897 $291.6K (12.8%). This concentration means changes in utilization, supply, or reimbursement for these specific agents would materially affect overall Medicare revenue for the provider.

The code mix is characteristic of an oncology infusion practice: large shares of revenue come from injectable monoclonal antibodies and cancer therapies (J9144, J9271, J0897) and the presence of chemotherapy administration codes such as 96413 and add-on infusion codes suggests routine on-site infusion and chemotherapy delivery. Supportive-care medication codes and frequent lab/venipuncture codes (80053, 36415, 85025) imply integrated outpatient services (infusion plus diagnostics) to manage oncology patients.

Competitive standing is bifurcated by drug: for daratumumab (J9144) the provider ranks #17 of 615 nationally at the 97th percentile and is described as notably above typical national volume, signaling a high-volume national position for that agent. Denosumab (J0897) also shows above-typical national volume, ranking #451 of 10057 (95th percentile), which together indicate the provider is a major administrator of these biologics relative to peers.

Other high-revenue drugs are more modest in scale: pembrolizumab (J9271) generates $438.6K but ranks #1157 of 1841 (36th percentile; typical, unremarkable volume), indicating pembrolizumab utilization is not a distinguishing competitive advantage for this provider compared with the daratumumab and denosumab strengths. Analysts should therefore differentiate between dominant agents (J9144/J0897) and commonly used agents where the provider is closer to median peer activity.

Visit and ancillary service volumes are elevated relative to peers: the E/M code 99214 is an extreme outlier, ranking #8902 of 479517 (98th percentile; extreme outlier, far above typical national volume), and infusion-related codes such as 96375 rank #102 of 5191 (98th percentile; notably above typical national volume). High percentile rankings for phlebotomy and lab panels (36415 at the 99th percentile; 80053 at the 96th percentile) corroborate substantial outpatient throughput and on-site support services.

The provider’s operations also include very high claim-count, low-dollar items that reflect routine supportive care workflows: J0881 shows 31.5K claims at $2 avg paid/claim for $63K revenue (2.8% of Medicare revenue) and J1439 shows 29.3K claims at $1 avg paid/claim for $29.3K revenue (1.3%). These patterns are consistent with frequent, low-reimbursement supportive therapies and inventory/administration processes that accompany high-volume infusion practice.

This is an established practitioner with a long active period: NPI enumerated 2007-06-15 (~19 years ago), which helps explain sustained Medicare volume and the development of an infusion- and diagnostics-oriented practice profile; longevity suggests existing referral flows and operational stability that underlie the observed billing concentrations.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

40 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	29,520	$40	$1.1M
J9271	Injection, pembrolizumab, 1 mg	10,200	$40	$438.6K
J0897	Injection, denosumab, 1 mg	16,200	$20	$291.6K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,100	$110	$115.9K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	31,500	$1	$63K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	480	$120	$57.6K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	310	$150	$47.9K
J1439	Injection, ferric carboxymaltose, 1 mg	29,250	$1	$29.3K
96401	The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient.	340	$70	$22.6K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	300	$70	$20.8K

Showing 1–10 of 40

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 40 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. New Jersey Distribution

Thomas Blom — 6 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — New Jersey

Full comparison — all codes billed, vs. state median

40 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	25	50	10,650	$40	$580.7K
J9144	1	10	9,090	$40	$480.3K
J0897	17	380	3,060	$20	$87.8K
84443	168	380	100	$20	$65.5K
80053	25	560	90	$10	$50.8K
82607	62	150	50	$10	$39.9K
J1439	46	70	34,880	$1	$36.5K
J0881	4	30	7,180	$1	$30.6K
J3490	16	120	70	$230	$30.2K
82378	16	30	70	$20	$29.8K

Showing 1–10 of 40

Related Providers

Other providers that share a Tax Identification Number (TIN) with Thomas Blom, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Peter Yi	NJ	Hematology & Oncology Physician	$1.3M	$0
John Sierocki	NJ	Medical Oncology Physician	$820.2K	$0
Andrew Costin	NY	Cardiovascular Disease Physician	$561.2K	$0
Casey Wong	NJ	Cardiovascular Disease Physician	$521.5K	$0
Ramya Vedula	NJ	Internal Medicine Physician	$442.9K	$0
Tanner Tridico	NJ	Internal Medicine Physician	$313.8K	$0
Paul Lacava	NJ	Internal Medicine Physician	$268.3K	$0
Richard Lee	NJ	Hematology & Oncology Physician	$256K	$0
Benjamin Gitterman	NJ	Internal Medicine Physician	$199.5K	$0
Steven Kazenoff	NJ	Dermatology Physician	$184.7K	$0

Nearby Providers

Other providers in the same ZIP code as Thomas Blom, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Community Options, Inc.	NJ	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$337.7M
Eden Autism Services.	NJ	Developmentally Disabled Services Day Training Agency	$0	$167M
Enable, Inc.	NJ	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$79.3M
Community Options Enterprises, Inc	NJ	Developmentally Disabled Services Day Training Agency	$0	$63.5M
Neighbours, Inc	NJ	Case Management Agency	$0	$55.3M
Princeton Healthcare System, A New Jersey Non-profit Corporation	NJ	Psychiatric Hospital Unit	$0	$34M
Beacon Specialized Living New Jersey, Inc.	NJ	Developmentally Disabled Services Day Training Agency	$0	$32.5M
Princeton Child Development Institute	NJ	Community/Behavioral Health Agency	$0	$15.2M
Lingraphicare America, Inc	NJ	Durable Medical Equipment & Medical Supplies	$0	$13.1M
Values Into Action Nj, Inc.	NJ	Case Management Agency	$0	$11.5M

Thomas Blom — Billing Profile & Reimbursement Data

Sign up for Thomas Blom — Billing Profile & Reimbursement Data policy alerts

Thomas Blom — Billing Profile & Reimbursement Data

Sign up for Thomas Blom — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References